Toshiaki Onitsuka
Affiliations: | 2009-2011 | Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Clinical Neuroscience Division, Laboratory of Neuroscience | Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States |
| 2012- | Kyushu University and Kyushu Hospital, Fukuoika, Japan |
Google:
"Toshiaki Onitsuka"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Martha Elizabeth Shenton | post-doc | 2000-2003 | Harvard Medical School - Brigham and Women's Hospital | |
| (Visiting Instructor at the PNL, HMS, Boston. Visiting Scholars Program, supported through funds from Kyushu University Medical School and by NIH funds.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Takai Y, Tamura S, Hoaki N, et al. (2024) Aberrant thalamocortical connectivity and shifts between the resting state and task state in patients with schizophrenia. The European Journal of Neuroscience |
| Nakanishi S, Tamura S, Hirano S, et al. (2023) Abnormal phase entrainment of low- and high-gamma-band auditory steady-state responses in schizophrenia. Frontiers in Neuroscience. 17: 1277733 |
| Okada N, Fukunaga M, Miura K, et al. (2023) Subcortical volumetric alterations in four major psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification. Molecular Psychiatry |
| Hashimoto N, Yasui-Furukori N, Hasegawa N, et al. (2023) Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project. Bmc Psychiatry. 23: 473 |
| Onitsuka T, Okada T, Hasegawa N, et al. (2023) Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan. Journal of Clinical Psychopharmacology |
| Kyou Y, Yasui-Furukori N, Hasegawa N, et al. (2022) The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)" project. Annals of General Psychiatry. 21: 52 |
| Fukumoto K, Kodaka F, Hasegawa N, et al. (2022) Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood Disorders. Neuropsychopharmacology Reports |
| Inada K, Fukumoto K, Hasegawa N, et al. (2022) Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia". Neuropsychopharmacology Reports |
| Okada T, Hori H, Hasegawa N, et al. (2022) Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia. Journal of Clinical Psychopharmacology |
| Kitajima K, Tamura S, Sasabayashi D, et al. (2022) Decreased Cortical Gyrification and Surface Area in the Left Medial Parietal Cortex in Patients with Treatment-Resistant and Ultra-Treatment-Resistant Schizophrenia. Psychiatry and Clinical Neurosciences |